SNY: מכפיל מחיר להכנסות Sanofi Aventis
Regarding the price-to-sales ratio, this chart on GURU.Markets shows that the metric is fixed at 2.20. Patent barriers and costly biotechnologies serve as a moat for the business. A network of modern plants in the US and Europe guarantees production stability. Monopoly rights to unique therapies allow Sanofi (SNY) to maintain its premium pricing power.
פילוחי מדדים ואנליטיקה של חברת Sanofi Aventis (SNY)
The P/S ratio determines the market value of Sanofi (SNY) relative to its annual revenue, measuring the premium investors are willing to pay for every euro of sales. For this veteran European manufacturer of vaccines and life-saving medicines, the price/sales ratio trend serves as an indicator of how closely the market valuation aligns with real commercial resilience and global trust in the company's brand.
